topical ruxolitinib 1.5% cream

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Oregon Health and Science University

Conditions

Non-sclerotic Cutaneous Chronic Graft-versus-host DiseasePyoderma Gangrenosum

Phase 2

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Active, not recruitingNCT03954236

Memorial Sloan Kettering Cancer CenterNon-sclerotic Cutaneous Chronic Graft-versus-host Disease

Start: 2019-05-14End: 2027-02-06Updated: 2026-07-10

Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum

Not yet recruitingNCT07783412

Oregon Health and Science UniversityPyoderma Gangrenosum

Start: 2026-09-01End: 2029-12-01Target: 12Updated: 2026-08-24

Related Papers

Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial.

2026-09-16